Wednesday, June 4, 2025

Atropos Health Named to the 2023 CB Insights’ Digital Health 50 List

Related stories

Snowflake Buys Crunchy Data for Enterprise Postgres in AI Cloud

Empowering enterprises across industries to build and deploy secure,...

Immuta Unveils AI to Speed Enterprise Data Provisioning

First-to-market features enable real-time, intelligent access decisions—eliminating manual reviews...

Cube Unveils D3: Agentic Analytics on Semantic Layer

Cube, the leading provider of semantic layer technology for...

IBM Launches watsonx AI Labs to Boost AI in NYC

New AI initiative will co-create gen AI solutions with...

Oxipital AI & Schmalz Partners for Advanced Automation

Oxipital AI, a pioneering force in AI-driven machine vision...
spot_imgspot_img

CB Insights named Atropos Health to its fifth-annual Digital Health 50 (formerly the Digital Health 150), showcasing the 50 most promising private digital health companies of 2023.

“From bringing clinical trials to underserved populations to developing new drugs and therapies, this year’s Digital Health 50 winners are transforming the future of healthcare,” said Alex Lennox-Miller, CB Insights’ Lead Healthcare Analyst. “Generative AI is continuing to gain traction in healthcare, with over thirty companies in this year’s cohort offering AI-augmented solutions. We are excited to follow the meaningful impact, industry-leading innovations, and continued success of this year’s winners.”

I am thrilled for the Atropos Health Team and its users and customers to receive this recognition,” said Co-Founder and CEO Dr. Brigham Hyde. “We are committed to providing evidence-based insights in order to drive better patient outcomes, accelerate drug discovery, and ultimately save healthcare and life science organizations significant time and expenses.”

Also Read: AI Pioneer Rainbird Technologies Names Klick Health as Its Exclusive North American Life Sciences Partner

The 50 winners were selected from a pool of over 10K companies, including applicants and nominees. They were chosen based on several factors, including CB Insights datasets — covering R&D activity, Mosaic scores, business relationships, software buyer transcripts, investor profiles, news sentiment analysis, competitive landscape, and team strength — along with criteria such as tech novelty, market potential, and impact on the industry.

Atropos Health is used by clinicians, researchers, physicians, and drug developers to close the global evidence gap while accelerating clinical trial and decision-making timelines. The company’s products include Geneva OS™(Generative Evidence Acceleration Operating System) and the ChatRWD™ (Real World Data) application, the first Generative AI application incorporating direct Chat-to-Database capability.

These offerings enable non technical users to generate publication grade Observational Research studies leveraging deidentified patient level real world data from the Atropos Evidence Network in a matter of minutes, saving organizations valuable time, money, and staffing resources. Geneva OS and ChatRWD work alongside Atropos’ evidence solutions – the Green Button Informatics Consult Service, Atropos Evidence Network, and the Atropos Evidence Library.

SOURCE: BusinessWire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img